Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer
This study has been completed.
North Central Cancer Treatment Group
Information provided by:
National Cancer Institute (NCI)
First received: July 5, 2000
Last updated: May 13, 2011
Last verified: April 2008
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Estimated Study Completion Date:||No date given|
|Primary Completion Date:||April 2008 (Final data collection date for primary outcome measure)|
Alberts SR, Reid JM, Morlan BW, Farr GH, Camoriano JK, Johnson DB, Enger JR, Seay TE, Kim GP. Gemcitabine and Docetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol. 2011 May 6; [Epub ahead of print]
Kim GP, Alberts SR, Tschetter LK, et al.: Gemcitabine and docetaxel in patients with measurable unresectable or metastatic hepatocellular carcinoma (HCC), a North Central Cancer Treatment Group (NCCTG) phase II trial. [Abstract] J Clin Oncol 22 (Suppl 14): A-4270, 380s, 2004.